DRREDDY
500124Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Employee Stock options
Dr. Reddy's Laboratories Ltd is a leading global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company develops, manufactures, and markets a wide spectrum of generic formulations, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter products.
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Employee Stock options
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of newspaper publication
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
Announcement under Regulation 30 (LODR)-Change in Management
Change in Senior Management Personnel
Dr Reddys Laboratories Ltd
About
Dr. Reddy's Laboratories Ltd is a leading global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company develops, manufactures, and markets a wide spectrum of generic formulations, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter products.
Dr. Reddy’s serves patients and healthcare professionals in over 60 countries, maintaining a strong presence in North America, Europe, India, Russia, and other emerging markets.
Known for its commitment to affordable healthcare, Dr. Reddy’s has robust R&D capabilities across multiple therapeutic areas, notably oncology, gastroenterology, cardiovascular, anti-infectives, and pain management. The company’s operations span innovation-driven product development, a global manufacturing network, and a growing focus on sustainability and digital transformation.
Business Model & Strategy
Dr. Reddy's Laboratories' core revenue model is built on the manufacture and global distribution of generic drugs, APIs, and proprietary pharmaceuticals. The company operates through the following segments: Global Generics—driving revenue through off-patent drugs in key regulated and emerging markets; Pharmaceutical Services and Active Ingredients (PSAI)—supplying APIs and custom pharmaceutical services to third parties; and Proprietary Products and Biosimilars—focused on differentiated products and specialty therapeutics.
The company leverages an extensive intellectual property portfolio, strategic in-licensing and partnerships, and capabilities in clinical development to drive growth.
Key growth vectors include launching first-to-market generics, expanding biosimilars, investing in R&D, digital health initiatives, and strategic acquisitions. Dr. Reddy’s continually invests in global regulatory compliance and operational efficiency, enabling it to enter new geographies, scale manufacturing, and accelerate pipeline commercialization.
Management Overview
13 MembersMr.Satish Reddy Kallam
Executive Director-ChairpersonMr.Venkateswara Prasad Gunupati
Executive DirectorMr.ErezIsraeli
Chief Executive OfficerMr.Leo Puri
Non-Executive - Independent DirectorMs.Shikha Sanjaya Sharma
Non-Executive - Independent DirectorMr.Kodumudi Pranatharthiharan Krishnan
Non-Executive - Independent DirectorMs.Penny Chan Wan
Non-Executive - Independent DirectorMr.Arun Madhavan Kumar
Non-Executive - Independent DirectorMr.Claudio Albrecht
Non-Executive - Independent DirectorMs.Alpna Hansraj Seth
Non-Executive - Independent DirectorMr.Sanjiv Soshil Mehta
Non-Executive - Independent DirectorMr.M V Narasimham
Chief Financial OfficerMr.K Randhir Singh
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- Included in Dow Jones Sustainability Emerging Markets Index (2023)
- Gold-level recognition from EcoVadis for Sustainability (2024)
- Ranked among India’s Most Trusted Brands in Healthcare by Brand Trust Report (2023)
- Awarded Great Place to Work® certification (2024)
- Recipient of the Frost & Sullivan India Pharma Supply Chain Leadership Award (2023)
Market Information
Company Timeline
40+ Years of Excellence | 11 Major Milestones
Company founded in Hyderabad, India.
First Active Pharmaceutical Ingredient (API) export.
Initial Public Offering (IPO) on Indian stock exchanges.
Entry into finished dosage segment.
US FDA approval for manufacturing facility; entry into US generics market.
Acquisition of Betapharm, Germany, expanding European presence.
First biosimilar launch in India.
Collaboration with RDIF for Sputnik V COVID-19 vaccine distribution in India.
Acquisition of select brands from Wockhardt Ltd, strengthening India portfolio.
Inclusion in Dow Jones Sustainability Emerging Markets Index.
Expansion of digital health and biosimilars divisions.
The Next Evolution
Contact Information
Registered Office
8-2-337, Road No. 3, Banjara Hills
Tel: 040-49002900,
Fax: 040-49002999,
Email: shares@drreddys.com; mail@drreddys.com
Website: drreddys.com
Corporate Actions
13| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹8 per share | 10 Jul 2026 Friday | 10 Jul 2026 Friday | - | - |
Final Dividend ₹8 per share | 10 Jul 2025 Thursday | 10 Jul 2025 Thursday | - | - |
Stock Split From Rs.5/- to Rs.1/- | 28 Oct 2024 Monday | 28 Oct 2024 Monday | - | - |
Final Dividend ₹40 per share | 16 Jul 2024 Tuesday | - | 17 Jul 2024 Wednesday | 19 Jul 2024 Friday |
Final Dividend ₹40 per share | 11 Jul 2023 Tuesday | - | 12 Jul 2023 Wednesday | 14 Jul 2023 Friday |
Final Dividend ₹30 per share | 11 Jul 2022 Monday | - | 13 Jul 2022 Wednesday | 15 Jul 2022 Friday |
Final Dividend ₹25 per share | 09 Jul 2021 Friday | - | 13 Jul 2021 Tuesday | 15 Jul 2021 Thursday |
Final Dividend ₹25 per share | 13 Jul 2020 Monday | - | 15 Jul 2020 Wednesday | 17 Jul 2020 Friday |
Final Dividend ₹20 per share | 15 Jul 2019 Monday | - | 17 Jul 2019 Wednesday | 19 Jul 2019 Friday |
Final Dividend ₹20 per share | 16 Jul 2018 Monday | - | 18 Jul 2018 Wednesday | 20 Jul 2018 Friday |
Dividend ₹20 per share | 17 Jul 2017 Monday | - | 19 Jul 2017 Wednesday | 21 Jul 2017 Friday |
Dividend ₹20 per share | 18 Jul 2016 Monday | - | 20 Jul 2016 Wednesday | 22 Jul 2016 Friday |
Final Dividend ₹20 per share | 10 Jul 2015 Friday | - | 14 Jul 2015 Tuesday | 17 Jul 2015 Friday |
₹97,741 Cr.
₹1,171
₹1,415 / 1,101
30.27
₹458.03
2.56
₹38.69
₹1.00
0.68 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 15,786 | 18,138 | 19,339 | 22,030 | 25,725 | 28,905 | 33,741 | 35,059 | 34,651 |
| Expenses | - | - | - | 13,494 | 16,308 | 16,503 | 19,039 | 19,714 | 21,719 | 26,083 | 29,679 | 30,624 |
| Profit | - | - | - | 1,950 | 2,026 | 1,952 | 2,183 | 4,507 | 5,578 | 5,725 | 4,158 | 3,183 |
| Tax | - | - | - | 386 | -140.30 | 932 | 879 | 1,541 | 1,623 | 1,954 | 1,235 | 858 |
| EPS | - | - | - | 118 | 122 | 118 | 132 | 271 | 335 | 68 | 50 | 5.33 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 22,466 | 23,225 | 26,617 | 29,747 | 32,285 | 38,864 | 49,427 | 58,123 | - |
| Equity And Liabilities | - | - | - | 22,466 | 23,225 | 26,617 | 29,747 | 32,285 | 38,864 | 49,427 | 58,123 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 16 Apr '19 | Mar 2020 17 Apr '20 | Mar 2021 16 Apr '21 | Mar 2022 20 Apr '22 | Mar 2023 01 Jun '23 | Mar 2024 19 Apr '24 | Mar 2025 19 Apr '25 | Mar 2026 05 May '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 26.77% | 26.75% | 26.74% | 26.72% | 26.70% | 26.65% | 26.64% | 26.63% | - |
| Non Institutions | - | - | - | 27.64% | 28.51% | 28.99% | 23.07% | 11.48% | 10.38% | 10.15% | 9.33% | - |
| FII | - | - | - | - | - | - | - | 38.55% | 44.49% | 37.29% | 33.08% | - |
| DII | - | - | - | - | - | - | - | 23.05% | 18.31% | 25.62% | 30.72% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd is a leading global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company develops, manufactures, and markets a wide spectrum of generic formulations, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter products.
Dr. Reddy’s serves patients and healthcare professionals in over 60 countries, maintaining a strong presence in North America, Europe, India, Russia, and other emerging markets.
Known for its commitment to affordable healthcare, Dr. Reddy’s has robust R&D capabilities across multiple therapeutic areas, notably oncology, gastroenterology, cardiovascular, anti-infectives, and pain management. The company’s operations span innovation-driven product development, a global manufacturing network, and a growing focus on sustainability and digital transformation.
Dr. Reddy's Laboratories' core revenue model is built on the manufacture and global distribution of generic drugs, APIs, and proprietary pharmaceuticals. The company operates through the following segments: Global Generics—driving revenue through off-patent drugs in key regulated and emerging markets; Pharmaceutical Services and Active Ingredients (PSAI)—supplying APIs and custom pharmaceutical services to third parties; and Proprietary Products and Biosimilars—focused on differentiated products and specialty therapeutics.
The company leverages an extensive intellectual property portfolio, strategic in-licensing and partnerships, and capabilities in clinical development to drive growth.
Key growth vectors include launching first-to-market generics, expanding biosimilars, investing in R&D, digital health initiatives, and strategic acquisitions. Dr. Reddy’s continually invests in global regulatory compliance and operational efficiency, enabling it to enter new geographies, scale manufacturing, and accelerate pipeline commercialization.
Included in Dow Jones Sustainability Emerging Markets Index (2023)
Gold-level recognition from EcoVadis for Sustainability (2024)
Ranked among India’s Most Trusted Brands in Healthcare by Brand Trust Report (2023)
Awarded Great Place to Work® certification (2024)
Recipient of the Frost & Sullivan India Pharma Supply Chain Leadership Award (2023)
Company founded in Hyderabad, India.
First Active Pharmaceutical Ingredient (API) export.
Initial Public Offering (IPO) on Indian stock exchanges.
Entry into finished dosage segment.
US FDA approval for manufacturing facility; entry into US generics market.
Acquisition of Betapharm, Germany, expanding European presence.
First biosimilar launch in India.
Collaboration with RDIF for Sputnik V COVID-19 vaccine distribution in India.
Acquisition of select brands from Wockhardt Ltd, strengthening India portfolio.
Inclusion in Dow Jones Sustainability Emerging Markets Index.
Expansion of digital health and biosimilars divisions.
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon